Tag: Chong Kun Dang Pharmaceutical Corporation
Can Cara Therapeutics buck the trend?
Cara Therapeutics (NASDAQ: CARA) recently posted its first quarter, 2019 results. The company reported a net loss of $22.0 million, or $0.56 per basic...
Emerging treatment approaches in Pruritus
Pruritus is characterized by an uncomfortable and persistent urge to scratch caused either due to a skin disorder or an underlying systemic disease such...
We are looking for talented interns to learn and help investors find valuable companies.